This global biotech company receives tentative approval from US FDA! This global biotech company receives tentative approval from US FDA! The company is committed to research and development, allocating 7.9 per cent of its revenue to this area in FY23. Siddharth Mane / Tuesday, July 4, 2023 / Article rating: 3.9 The company has delivered returns of 41.8 per cent over the past year.